​

Organogenesis (ORGO) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

ORGO Stock Forecast

Organogenesis (ORGO) stock forecast, based on 5 Wall Street analysts, predicts a 12-month average price target of $9.00, with a high of $9.00 and a low of $9.00. This represents a 239.62% increase from the last price of $2.65.

$2 $3 $4 $5 $6 $7 $8 $9 High: $9 Avg: $9 Low: $9 Last Closed Price: $2.65

ORGO Stock Rating

Organogenesis stock's rating consensus is Buy, based on 5 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 4 Buy (80.00%), 1 Hold (20.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 5 0 1 4 Strong Sell Sell Hold Buy Strong Buy

ORGO Price Target Upside V Benchmarks

TypeNameUpside
StockOrganogenesis239.62%
SectorHealthcare Stocks 15.45%
IndustrySpecialty & Generic Drug Manufacturers Stocks25.21%

Price Target Trends

1M3M12M
# Anlaysts--1
Avg Price Target--$9.00
Last Closing Price$2.65$2.65$2.65
Upside/Downside--239.62%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Mar, 26-2---2
Feb, 26-2---2
Jan, 26-2---2
Dec, 25-2---2
Nov, 25-2---2
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Nov 20, 2025BTIG$9.00$5.1475.10%239.62%
Mar 05, 2025Morgan Stanley$6.00$6.01-0.17%126.42%
Jun 28, 2024Brooks O'NeilLake Street$5.00$2.6489.39%88.68%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Dec 26, 2025BTIGBuyBuyhold
Nov 20, 2025BTIGBuyBuyhold
Jul 15, 2025BTIGBuyBuyhold
Jun 28, 2024Lake StreetBuyinitialise
Dec 27, 2023BTIGBuyBuyhold
May 24, 2023WestPark CapitalHoldinitialise
May 24, 2023BTIGBuyupgrade

Financial Forecast

EPS Forecast

Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26
Reported$0.73$0.12$0.04$-0.01$0.16-
Avg Forecast$0.42$0.12$0.07$-0.07$0.03$0.11
High Forecast$0.43$0.12$0.08$-0.06$0.06$0.24
Low Forecast$0.41$0.12$0.05$-0.08$-0.01$0.04
Surprise %73.81%--42.86%-85.71%433.33%-

Revenue Forecast

$400M $440M $480M $520M $560M $600M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26
Reported$467.36M$450.89M$433.14M$482.04M$564.17M-
Avg Forecast$463.90M$458.80M$441.70M$465.62M$472.93M$510.63M
High Forecast$475.02M$469.96M$455.79M$480.47M$488.02M$510.63M
Low Forecast$456.28M$449.04M$430.02M$453.30M$460.42M$510.63M
Surprise %0.75%-1.72%-1.94%3.53%19.29%-

Net Income Forecast

$-50M $-20M $10M $40M $70M $100M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26
Reported$94.20M$15.53M$4.95M$861.00K$56.91M-
Avg Forecast$55.15M$15.93M$8.66M$-9.73M$1.87M$13.14M
High Forecast$56.87M$16.43M$10.39M$-8.34M$8.18M$32.24M
Low Forecast$53.97M$15.49M$6.92M$-11.13M$-1.02M$4.84M
Surprise %70.80%-2.50%-42.87%-108.84%2949.14%-

ORGO Forecast FAQ

Is Organogenesis stock a buy?

Organogenesis stock has a consensus rating of Buy, based on 5 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 4 Buy, 1 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Organogenesis is a favorable investment for most analysts.

What is Organogenesis's price target?

Organogenesis's price target, set by 5 Wall Street analysts, averages $9 over the next 12 months. The price target range spans from $9 at the low end to $9 at the high end, suggesting a potential 239.62% change from the previous closing price of $2.65.

How does Organogenesis stock forecast compare to its benchmarks?

Organogenesis's stock forecast shows a 239.62% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the specialty & generic drug manufacturers stocks industry (25.21%).

What is the breakdown of analyst ratings for Organogenesis over the past three months?

  • March 2026: 0% Strong Buy, 100.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • February 2026: 0% Strong Buy, 100.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • January 2026: 0% Strong Buy, 100.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Organogenesis’s EPS forecast?

Organogenesis's average annual EPS forecast for its fiscal year ending in December 2026 is $0.11, marking a -31.25% decrease from the reported $0.16 in 2025..

What is Organogenesis’s revenue forecast?

Organogenesis's average annual revenue forecast for its fiscal year ending in December 2026 is $510.63M, reflecting a -9.49% decrease from the reported $564.17M in 2025.

What is Organogenesis’s net income forecast?

Organogenesis's net income forecast for the fiscal year ending in December 2026 stands at $13.14M, representing a -76.91% decrease from the reported $56.91M in 2025.